戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 lectable marker that conferred resistance to mycophenolic acid.
2 v gene, we generated cell lines resistant to mycophenolic acid.
3      The enzyme was very weakly inhibited by mycophenolic acid.
4 id show some activity, albeit much less than mycophenolic acid.
5 lactone moiety were much less cytotoxic than mycophenolic acid.
6 tions of leflunomide and brequinar sodium or mycophenolic acid.
7 r discontinue (n = 25) mycophenolate mofetil/mycophenolic acid.
8 asiliximab, corticosteroids, tacrolimus, and mycophenolic acid.
9 ton pump inhibitors (PPI) reduce exposure of mycophenolic acid.
10  ribosomal stress caused by actinomycin D or mycophenolic acid.
11 vity, the target enzyme of the active moiety mycophenolic acid.
12 cardiovascular disease in patients receiving mycophenolic acid.
13 tly (P=0.001) higher 1-year trough levels of mycophenolic acid (4.16 ng/mL) than cyclosporine-treated
14 rget area under the time-concentration curve-mycophenolic acid: 75 mug.hr/mL).
15                                              Mycophenolic acid, a drug which reduces GTP levels and i
16        Mycophenolate mofetil did not provide mycophenolic acid absorption as well as EC-MPS.
17                        EC-MPS has become the mycophenolic acid agent of choice at this large center.
18 id, were used in the synthesis of monocyclic mycophenolic acid analogues 2a-i.
19 All patients received basiliximab induction, mycophenolic acid and corticosteroids.
20 e Set1-Set3 complex pathway are sensitive to mycophenolic acid and have reduced polymerase levels at
21 s are sensitive to the drugs 6-azauracil and mycophenolic acid and interact genetically with the elon
22 nhibitors of SARS-CoV-2, including imatinib, mycophenolic acid and quinacrine dihydrochloride.
23 ed degradation were identified as isomers of mycophenolic acid and sorbitol esters using Q-ToF LC-MS
24 ine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A (E
25          However, the lack of sensitivity to mycophenolic acid and the Km for NAD (1180 microM) exemp
26  effect was abrogated by GTP depletion using mycophenolic acid and was restored upon GTP repletion by
27  vitro bradyzoite formation and treated with mycophenolic acid and xanthine to positively select for
28  selected for by growth in medium containing mycophenolic acid and xanthine.
29  anti-flaviviral drugs (e.g., bortezomib and mycophenolic acid) and others that had no previously kno
30 f tacrolimus as calcineurin inhibitor (CNI), mycophenolic acid, and glucocorticoids.
31 teraction was observed between cyclosporine, mycophenolic acid, and RAL.
32 pients treated with alemtuzumab, tacrolimus, mycophenolic acid, and steroids.
33                     Exposures to tacrolimus, mycophenolic acid, and total and free prednisolone were
34  toxicity, could be obtained with ribavirin, mycophenolic acid, and viramidine.
35                                     However, mycophenolic acid, another IMPDH inhibitor, had no antiv
36 and steroids (AOR, 1.42; 95% CI, 1.11-1.82), mycophenolic acid (AOR, 1.29; 95% CI, 1.02-1.64), siroli
37 ds ratio [AOR], 1.60; 95% CI, 1.49-1.73) and mycophenolic acid (AOR, 1.37; 95% CI, 1.25-1.51) were as
38  steroids (AOR, 1.60; 95% CI, 1.38-1.86) and mycophenolic acid (AOR, 1.61; 95% CI, 1.37-1.90) were as
39 hibitors, steroids, or mycophenolate mofetil/mycophenolic acid are associated with an increased risk
40 ophosphate together with a second inhibitor, mycophenolic acid, are presented here.
41 oglobulin as induction agent, tacrolimus and mycophenolic acid as maintenance therapy.
42          The values of Km for NAD and Ki for mycophenolic acid as well as the synergistic interaction
43 5, and recipients were converted from CsA to mycophenolic acid at 6 months posttransplantation.
44 itors of this enzyme such as 6-azauracil and mycophenolic acid, at least partly because of their inab
45 5), acute rejection (AHR, 5.4; P<0.001), and mycophenolic acid AUC0-12 hr more than 50 hr mg/L (AHR,
46 in a negatively cooperative fashion and that mycophenolic acid binding is critically dependent on the
47 ffects of substrate, product, and inhibitor (mycophenolic acid) binding on the conformation and stabi
48 .9% versus 100%, P < 0.001), with especially mycophenolic acid, but also, higher age, lower lymphocyt
49 ofiles identified for the immunosuppressants mycophenolic acid, cyclosporin A, and FK-506 provide a p
50 rst, depletion of GTP by treating cells with mycophenolic acid decreased the level of NS without appa
51 sformants were isolated under selection with mycophenolic acid, demonstrating the feasibility of HXGP
52                                   The use of mycophenolic acid did not impact on the response to riba
53         The proportion of patients receiving mycophenolic acid dose equal to or more than 2000 mg per
54 ced by overlapping toxicity with concomitant mycophenolic acid, exploration of alternative adjunctive
55      In post hoc analysis, patients with low mycophenolic acid exposure (AUC <50 microgh/ml) experien
56           It is possible that a reduction in mycophenolic acid exposure contributed to the increased
57                           The defined higher mycophenolic acid exposure was well tolerated.
58 g rat islets in the presence of 25 microg/ml mycophenolic acid for 20 h.
59 the rate and extent of absorption of SRL and mycophenolic acid from EC-MPS were similar.
60    Mycophenolate Mofetil (MMF), a prodrug of mycophenolic acid, has clinical utility for the treatmen
61 nosine monophosphate dehydrogenase inhibitor mycophenolic acid have been explored.
62 ) = 0.1 microM, respectively) as potently as mycophenolic acid (IC(50) = 0.3 microM).
63 ntly than tiazofurin (IC50 = 12.4 microM) or mycophenolic acid (IC50 = 7.7 microM).
64 sodium in the MLC, and from cyclosporine and mycophenolic acid in both MLC and CTLL-4.
65 ive a compound with 2-4 times the potency of mycophenolic acid in vitro and in vivo.
66 mational changes occur during the normal and mycophenolic acid-inhibited reaction sequences of IMPDH.
67                                              Mycophenolic acid inhibition appeared to impart even gre
68  pronounced resistance of C. parvum IMPDH to mycophenolic acid inhibition is in strong agreement with
69                              We propose that mycophenolic acid inhibits IMPDH by trapping a transient
70                                              Mycophenolic acid inhibits the purine pathway and subseq
71                                  Plasma-free mycophenolic acid levels of 10 to 30 microg/mL were asso
72 nsplant patients who received belatacept and mycophenolic acid maintenance immunosuppression is repor
73  maintenance for 3 months and then sirolimus-mycophenolic acid maintenance thereafter.
74 oup of patients suggest that belatacept with mycophenolic acid may be a safe maintenance immunosuppre
75 The 10 cases were treated with azathioprine, mycophenolic acid, methotrexate, or infliximab.
76 TTV load in sera of 76 KTRs, with 43 pausing mycophenolic acid (MPA) 1 wk before to 4 wk after COVID-
77  reduced-exposure cyclosporine A (CsA) or to mycophenolic acid (MPA) 1.44 g per day plus standard-exp
78 mainly related to immunosuppressive drugs as mycophenolic acid (MPA) and anti-infectious agents, but
79  their lower affinity for inhibitors such as mycophenolic acid (MPA) and thiazole-4-carboxamide adeni
80 pients were concentration controlled to keep mycophenolic acid (MPA) C0 levels at 1.8-4 microg/ml.
81                 In a multivariable analysis, mycophenolic acid (MPA) dose and hemoglobin level were f
82 /d and dose adjusted from day 5 according to mycophenolic acid (MPA) exposure (arm A) or a regimen wi
83             Previous studies have shown that mycophenolic acid (MPA) has an anti-HCV activity.
84 ehydrogenase (IMPDH) in complex with IMP and mycophenolic acid (MPA) has been determined by X-ray dif
85 rmined, and the inhibitory effect of XMP and mycophenolic acid (MPA) has been studied.
86                  The immunosuppressant agent mycophenolic acid (MPA) has shown clinical efficacy for
87 by tacrolimus, everolimus, prednisolone, and mycophenolic acid (MPA) in clinically relevant concentra
88  this issue of Blood, Nguyen et al show that mycophenolic acid (MPA) induces GTP depletion, which inh
89                                              Mycophenolic acid (MPA) is a highly effective immunosupp
90                                              Mycophenolic acid (MPA) is a potent and specific inhibit
91                                              Mycophenolic acid (MPA) is a potent inhibitor of mammali
92                                              Mycophenolic acid (MPA) is a species-specific inhibitor
93                                              Mycophenolic acid (MPA) is a standard immunosuppressant
94                                              Mycophenolic acid (MPA) is an immunosuppressant drug com
95                                              Mycophenolic acid (MPA) is an inhibitor of lymphocyte pr
96                                              Mycophenolic acid (MPA) is commonly used in immunosuppre
97                                              Mycophenolic acid (MPA) is the active immunosuppressive
98                                              Mycophenolic acid (MPA) is the active metabolite of myco
99                                              Mycophenolic acid (MPA) is the active metabolite of myco
100 echanisms underlying the negative effects of mycophenolic acid (MPA) on human intestinal cells.
101 independent PKC isoforms, in comparison with mycophenolic acid (MPA) on rat renal transplants with pr
102 amines the effects of MMF's active component Mycophenolic Acid (MPA) on the transcriptome of podocyte
103                                          The mycophenolic acid (MPA) preparations are one of the most
104                                Additionally, mycophenolic acid (MPA) products are teratogenic.
105 rations of tacrolimus/cyclosporine (CsA) and mycophenolic acid (MPA) singly or in combination had no
106 cs, PD) in allograft recipients treated with mycophenolic acid (MPA) to determine its mechanisms and
107  from fixed dosing ("one-dose-fits-all"), to mycophenolic acid (MPA) trough concentration monitoring,
108 t biopsies (n=246), and serum daclizumab and mycophenolic acid (MPA) trough levels were evaluated.
109                         Tacrolimus (TAC) and mycophenolic acid (MPA) trough levels were measured from
110 ultaneously in the synthesis of analogues of mycophenolic acid (MPA) was explored.
111                                              Mycophenolic acid (MPA) was withdrawn in 41 KTRs 1 wk be
112 ylprednisolone (MP), methotrexate (MTX), and mycophenolic acid (MPA) were added to the final 6 days o
113                      Control groups received mycophenolic acid (MPA) with standard-dose cyclosporine.
114              We have examined the effects of mycophenolic acid (MPA), a potent IMPDH inhibitor, on th
115       The conformation of the sodium salt of mycophenolic acid (MPA), a potent inhibitor of inosine m
116                                              Mycophenolic acid (MPA), a selective inhibitor of inosin
117  have examined the induction of apoptosis by mycophenolic acid (MPA), a specific IMPDH inhibitor, in
118 . albicans cells is inhibited at 1 microg of mycophenolic acid (MPA), a specific inhibitor of IMP deh
119                    We have demonstrated that mycophenolic acid (MPA), a specific inosine monophosphat
120                                              Mycophenolic acid (MPA), an immunosuppressive drug, was
121                                              Mycophenolic acid (MPA), an inhibitor of IMP-dehydrogena
122    Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), an inhibitor of inosine-5'-mono
123                   This activity is shared by mycophenolic acid (MPA), an inhibitor of purine biosynth
124 ponses were inhibited by tacrolimus (FK506), mycophenolic acid (MPA), and cyclosporine (CsA) in a dos
125 ompared between KTRs treated with mTORis and mycophenolic acid (MPA), and in vitro mTORi effects on T
126 splant recipients on calcineurin inhibitors, mycophenolic acid (MPA), and prednisone with IFTANOS, su
127                                         BEL, mycophenolic acid (MPA), and sirolimus, either alone or
128 ophosphate dehydrogenase inhibitors, such as mycophenolic acid (MPA), induce the differentiation of P
129 prototypic uncompetitive inhibitor of IMPDH, mycophenolic acid (MPA), is the active form of mycopheno
130    Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is widely used as an immunosupp
131 equency was measured in the presence of RBV, mycophenolic acid (MPA), selenazofurin, or tiazofurin.
132        We evaluated plasma concentrations of mycophenolic acid (MPA), the active metabolite of MMF, a
133               Here, we studied the effect of mycophenolic acid (MPA), the active metabolite of mycoph
134 ith its substrate IMP, IMP and the inhibitor mycophenolic acid (MPA), the product XMP with MPA, and X
135 rostate PC-3 tumor cell line as a target and mycophenolic acid (MPA), tiazofurin, or ribavirin, which
136 of targeting a model immunosuppressant drug, mycophenolic acid (MPA), to T cells in the MLN, using a
137 ote the delivery of a model immunomodulator, mycophenolic acid (MPA), to the lymphatic system after o
138 ined by reduction of the carboxylic group of mycophenolic acid (MPA), was coupled with 2',3'-O-isopro
139 ompactum produces the immunosuppressive drug mycophenolic acid (MPA), which is a potent inhibitor of
140  rapidly hydrolyzed to its active metabolite mycophenolic acid (MPA), which is excreted by the kidney
141 ch was previously identified as resistant to mycophenolic acid (MPA).
142 e turnover events accompanying inhibition by mycophenolic acid (MPA).
143 ibition of purine nucleotide biosynthesis by mycophenolic acid (MPA).
144 g delivery vehicle for the immunosuppressant mycophenolic acid (MPA).
145 itation, and the IMP dehydrogenase inhibitor mycophenolic acid (MPA).
146 gan transplantation, is a prodrug to deliver mycophenolic acid (MPA).
147 en and experimental drug therapies including mycophenolic acid (MPA).
148 CNI (tacrolimus), steroids and alternatively Mycophenolic Acid (MPA, n=38) or mTORi (either everolimu
149 CNI (tacrolimus), steroids and alternatively mycophenolic acid (MPA; n = 38), or mTORi (either everol
150 ], AVN-944, mycophenolate mofetil [MMF], and mycophenolic acid [MPA]), but not obatoclax or Osu-03012
151 idney transplant patients in the prospective Mycophenolic Acid Observational Renal Transplant registr
152 ta do not demonstrate a consistent effect of mycophenolic acid on dnDSA production.
153                                              Mycophenolic acid or doxorubicin induced NS degradation
154 tratified by treatment with corticosteroids, mycophenolic acid, or both (yes or no).
155 nce of pharmacological concentrations FK506, mycophenolic acid, or cyclosporine-A.
156 f RTF1 causes sensitivity to 6-azauracil and mycophenolic acid, phenotypes correlated with a transcri
157 4 week surveillance and subsequent as needed mycophenolic acid predose concentrations during the firs
158 intenance immunosuppression with tacrolimus, mycophenolic acid prodrugs, and prednisone.
159 ucted to evaluate risks for BPAR relating to mycophenolic acid product.
160                    The drugs 6-azauracil and mycophenolic acid reduce both the elongation rate and pr
161                A common strategy to mitigate mycophenolic acid-related GI adverse events includes dos
162  contain the HIV-1 genome with the bacterial mycophenolic acid resistance gene gpt in place of the vi
163 the NOT4 gene elicited 6-azauracil (6AU) and mycophenolic acid sensitivities, hallmarks of transcript
164 ancies should be planned and the teratogenic mycophenolic acid should be replaced with azathioprine b
165                     This study suggests that mycophenolic acid, sirolimus, and steroids are associate
166 rium is perturbed in the presence of IMP and mycophenolic acid, suggesting a mechanism for the ligand
167    Addition of clinically relevant levels of mycophenolic acid, the active agent for MMF, added to mo
168 ed by male recipients, including patients on mycophenolic acid therapy at the time of conception, is
169 hate (IMP), and the uncompetitive inhibitor, mycophenolic acid, to inosine monophosphate dehydrogenas
170 th mycophenolate mofetil (MMF; target plasma mycophenolic acid trough level of 1.5-2.5 microg/ml) or
171  reduction of cardiac allograft rejection by mycophenolic acid was accompanied by reduced CD40 ligand
172 n-organic vegetables, where sulfadiazine and mycophenolic acid were detected.
173 e (E)-4-methyl-4-hexenoic acid side chain of mycophenolic acid, were used in the synthesis of monocyc
174 phate dehydrogenase inhibitors ribavirin and mycophenolic acid, which are already in clinical use, sh

 
Page Top